median survival among patients whose serum CEA concentration fell after chemotherapy (70%/o of patients treated) compared with patients whose serum CEA did not fall. The use of >25% clinical or radiological tumour shrinkage as a predictor of prolonged survival identified a smaller proportion (36%) of patients in whom there was a 52% prolongation in median survival compared with patients whose tumours shrank less than 25%, or did not shrink. Proportional hazards regression analysis suggested that tumour shrinkage was a stronger predictor of survival. A fall in serum CEA concentration, however, identified a group of patients whose tumours did not shrink, but who had a 27% improvement in median survival compared with those whose tumours did not shrink and whose serum CEA concentration did not fall. Monitoring of the serum CEA during the first two months of treatment appears to provide a sensitive and economical means of identifying those patients whose survival is likely to be prolonged by chemotherapy for colorectal cancer.
The value of serum carcinoembryonic antigen (CEA) monitoring in the detection of recurrent colorectal cancer has been established.' Some patients with recurrent disease can be treated by a second surgical resection but for most, cytotoxic chemotherapy offers the only chance of slowing the progress of the disease. The potential benefits of effective chemotherapy are a prolongation of survival and an improvement in performance status.
It would be useful to establish criteria which could identify early, those patients whose survival will be prolonged by chemotherapy. It is generally assumed that clinical or radiological evidence of tumour shrinkage, referred to as response, is associated with Months from proocol entry Fig. 1 There was a significant (p<O.OOOOI) improvement in the survival ofpatients whose tumours decreased >25% after chemotherapy (O) compared with patients whose tumours decreased by <25% or did not change (X).
cent of these patients in whom the serum CEA fell experienced a fall of >20% of the initial serum CEA value. The serum CEA remained stable or continued to rise in the remaining 30% of the patients. Among the patients in whom the serum CEA fell after chemotherapy median survival was 12 months (CL 11 -0-13-7 months) which was significantly (p=0-0002) longer than a median survival of 8-8 months (CL 6-7-10-5 months) for those with no fall in serum CEA (Fig. 2) . Allowing for an error in the measurement of serum CEA decrease, patients in whom serum CEA fell >10% from baseline after chemotherapy were compared with those with no fall, stable values or a <10% fall. Those with a >10% fall in CEA had a significantly longer survival (p=0O0002 Tick mark (X) indicates lost follow-up a 0 00 9 00 1800 27 00 36 00 Months from protocol entry 45-00 Fig. 3 Among patients in whom tumourshrinkage of >25% did not occur (non-responders) there was a significant (p=004) improvement in survival among those in whom the serum CEA concentration fell (O) compared with those in whom CEA did notfall (X).
CEA decrease experienced significantly (p=0-04) longer survival than patients whose CEA rose or remained the same (Fig. 3) . The estimated median survival in non-responders whose serum CEA fell was 10-2 months (CL 9-0-12-0 months) versus 8-0 months (CL 6-1-9-0 months) for the remaining nonresponders with no fall in serum CEA.
Univariate survival analyses indicated that KPS, LDH, alk phos, and type of treatment were significantly related to survival (Table 1) . Alkaline phosphatase, however, was not included in the final model because it was not significant in the multivariate analysis. Allowing for initial KPS, serum LDH and type of treatment, a fall in the serum CEA remained a significant predictor of improved survival (improvement X2 p=0-001). In addition a fall in serum CEA remained predictive of survival even when eventual response status was considered in the analysis (improvement x2 p=0O008).
STABLE DISEASE SUBGROUP
In sixty three patients the serum CEA concentration did not increase or decrease more than 20% from pretreatment baseline. There was no significant difference (p=0-4) between the survival curves of patients whose CEA concentration fell by <20%, median survival 12-0 months (CL 6-0 -11-5 months) compared with patients whose CEA level rose by <20% or remained the same, median survival 8-6 months (CL 6-0-11-5 months). With this sample size the power to detect a difference is 60%.9 CEA is a poor predictor of tumour shrinkage because while it is sensitive (low false negative) it is also nonspecific (high false positive).
Rather than regarding tumour shrinkage as an objective of treatment, another approach is to consider survival as the endpoint of analysis and to seek to identify predictors of improved survival arising from chemotherapy. The results of our study indicate that a fall in the serum CEA concentration after chemotherapy, although not an accurate reflection of eventual tumour shrinkage, did identify patients whose survival was enhanced by chemotherapy. The estimated median survival for patients who experienced a fall in serum CEA was 12-0 months. If this group was characterised further as those experiencing a CEA reduction of <20%, 
